{"id":"individual-antithymocyte-globulin","safety":{"commonSideEffects":[{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Fever and chills"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Leukopenia"},{"rate":null,"effect":"Serum sickness"},{"rate":null,"effect":"Infection (due to immunosuppression)"}]},"_chembl":{"chemblId":"CHEMBL2108699","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ATG is produced by immunizing animals (typically rabbits or horses) with human thymocytes, generating a heterogeneous mixture of antibodies against T-cell antigens. These antibodies bind to circulating and tissue-resident T lymphocytes, leading to their destruction through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. This profound T-cell depletion reduces rejection responses in transplantation and modulates autoimmune conditions.","oneSentence":"Antithymocyte globulin (ATG) is a polyclonal antibody preparation that depletes T lymphocytes by binding to and eliminating T cells, thereby suppressing cell-mediated immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:51.706Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of acute rejection in organ transplantation"},{"name":"Treatment of aplastic anemia"},{"name":"Graft-versus-host disease (GVHD) prophylaxis and treatment"}]},"trialDetails":[{"nctId":"NCT00716066","phase":"PHASE2","title":"Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2008-06","conditions":"Autoimmune Disease, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune","enrollment":53},{"nctId":"NCT05166967","phase":"PHASE3","title":"Targeted Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2022-01-01","conditions":"Haploidentical Hematopoietic Stem Cell Transplantation","enrollment":204},{"nctId":"NCT03292861","phase":"PHASE2","title":"The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-09-13","conditions":"Heart Transplantation","enrollment":60},{"nctId":"NCT04778618","phase":"PHASE2","title":"Individualized Dose Study of ATG in Haploidentical Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2020-12-01","conditions":"Haploidentical Hematopoietic Stem Cell Transplantation","enrollment":63},{"nctId":"NCT05634915","phase":"PHASE4","title":"Clinical Study of rATG Individualized Administration in Haploidentical Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2022-12-20","conditions":"Hematopoietic Stem Cell Transplantation, Acute Leukemia","enrollment":90},{"nctId":"NCT02282514","phase":"PHASE1, PHASE2","title":"Stem Cell Transplantation for Stiff Person Syndrome (SPS)","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2014-10","conditions":"Stiff-Person Syndrome","enrollment":23},{"nctId":"NCT02411084","phase":"PHASE3","title":"Study of BEGEDINA® vs \"Conventional Treatment\" for Treating Steroid-Resistant Acute GvHD","status":"TERMINATED","sponsor":"Adienne SA","startDate":"2016-02","conditions":"Graft vs Host Disease","enrollment":36},{"nctId":"NCT00176878","phase":"PHASE2, PHASE3","title":"Stem Cell Transplant for Bone Marrow Failure Syndromes","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2000-06","conditions":"Diamond-Blackfan Anemia, Kostmann's Neutropenia, Shwachman-Diamond Syndrome","enrollment":10},{"nctId":"NCT01530555","phase":"PHASE2","title":"Prospective Phase II Study of Rabbit Antithymocyte Globulin (ATG, Thymoglobuline®, Genzyme) With Ciclosporin for Patients With Acquired Aplastic Anaemia","status":"COMPLETED","sponsor":"King Faisal Specialist Hospital & Research Center","startDate":"2008-04","conditions":"Acquired Aplastic Anaemia","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2661,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Individual Antithymocyte globulin","genericName":"Individual Antithymocyte globulin","companyName":"Chinese PLA General Hospital","companyId":"chinese-pla-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Antithymocyte globulin (ATG) is a polyclonal antibody preparation that depletes T lymphocytes by binding to and eliminating T cells, thereby suppressing cell-mediated immune responses. Used for Prevention of acute rejection in organ transplantation, Treatment of aplastic anemia, Graft-versus-host disease (GVHD) prophylaxis and treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}